(Q35017798)

5 August 2017

1 reference

title

Hepatitis C viral dynamics: basic concept and clinical significance (English)

1 reference

5 August 2017

Wolfgang Jessner

1

1 reference

5 August 2017

Thomas Watkins-Riedel

2

1 reference

5 August 2017

Elisabeth Formann

3

1 reference

5 August 2017

Petra Steindl-Munda

4

1 reference

5 August 2017

Peter Ferenci

5

1 reference

5 August 2017

publication date

1 December 2002

1 reference

Journal of Clinical Virology

5 August 2017

published in

1 reference

5 August 2017

volume

25 Suppl 3

1 reference

5 August 2017

page(s)

S31-9

1 reference

Hepatitis C viral kinetics in difficult to treat patients receiving high dose interferon and ribavirin

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Performance of the New Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, assay

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Nucleic acid testing: update and applications

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection. A randomized multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Hepatitis C virus kinetics during induction and standard 3 times a week interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Multicenter randomized study comparing initial daily induction with high dose lymphoblastoid interferon vs. standard interferon treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Combination of interferon induction therapy and ribavirin in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Comparative Evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0, and COBAS AMPLICOR HCV MONITOR Version 2.0 Assays for Quantification of Hepatitis C Virus RNA in Serum

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Efficacy of daily induction dosing vs standard thrice weekly dosing of interferon-alpha2B for initial treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Induction interferon therapy in naïve patients with chronic hepatitis C: increased end-of-treatment virological responses but absence of long-term benefit

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Automation of laboratory testing for infectious diseases using the polymerase chain reaction-- our past, our present, our future

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Performance characteristics of the COBAS Amplicor Hepatitis C Virus (HCV) Monitor, Version 2.0, International Unit assay and the National Genetics Institute HCV Superquant assay

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

How can mathematics help us understand HCV?

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD).

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Role of the specific T-cell response for clearance and control of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Hepatitis C virus resistance to antiviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Standardization of hepatitis C virus RNA quantification

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

How cells respond to interferons

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900194-4

7 January 2021

10.1016/S1386-6532(02)00194-4

Identifiers

DOI

1 reference

5 August 2017

1 reference